SCHEMBL23548279

SCHEMBL23548279

COCCNC(=O)[C@@H]1CC[C@@H](Nc2ncc3c(Br)nn(-c4ccc5nc(C)ccc5c4)c3n2)C1

nearest known ligand 0.82

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ EIF2AK4 Q9P2K8 20/20 0.82

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23548942 0.90 EIF2AK4 (1.00) EIF2AK4
SCHEMBL23548661 0.90 EIF2AK4 (1.00) EIF2AK4
SCHEMBL23548350 0.89 EIF2AK4 (0.74) EIF2AK4
SCHEMBL23548325 0.89 EIF2AK4 (0.85) EIF2AK4
SCHEMBL23548947 0.88 EIF2AK4 (0.81) EIF2AK4
SCHEMBL23548872 0.88 EIF2AK4 (0.78) EIF2AK4
SCHEMBL23548356 0.88 EIF2AK4 (0.78) EIF2AK4
SCHEMBL23548360 0.87 EIF2AK4 (0.89) EIF2AK4
SCHEMBL16022170 0.87 EIF2AK4 (0.62) EIF2AK4
SCHEMBL23548381 0.86 EIF2AK4 (0.73) EIF2AK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11046699-B2 Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses RAPT THERAPEUTICS, INC. (US) 2021-06-29 — — US disclosed
US-11046699-B2 Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses RAPT THERAPEUTICS, INC. (US) 2021-06-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11046699-B2 Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses GLS, GLS2, TK2 EIF2AK4 1089/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback